ScholarIQanswers from OpenAlex & ORCID
György Losonczy
ResearcherPublications, citations & collaboration network
György Losonczy is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does György Losonczy have?
ScholarIQindexed works
György Losonczy has 372 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does György Losonczy have?
ScholarIQcitation count
György Losonczy has 17,506 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of György Losonczy?
ScholarIQh-index
György Losonczy has an h-index of 46 in OpenAlex.
What is the i10-index of György Losonczy?
ScholarIQi10-index
György Losonczy has an i10-index of 113 in OpenAlex.
What is the ORCID of György Losonczy?
ScholarIQorcid
The ORCID for György Losonczy is on the source record.
What is the OpenAlex record for György Losonczy?
ScholarIQopenalex
The OpenAlex for György Losonczy is on the source record.
What are the most-cited papers on György Losonczy?
ScholarIQmost cited works
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna, Libor Havel, Maciej Krzakowski, Maximilian J. Hochmair, Florian Huemer, György Losonczy, Melissa L. Johnson, Makoto Nishio, Martin Reck, Tony Mok, Sivuonthanh Lam, David S. Shames, Juan Liu, Beiying Ding, Ariel López-Chávez, Fairooz F. Kabbinavar, Wei Lin, Alan Sandler, Stephen V. Liu
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Олександр Войтко, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Każarnowicz, György Losonczy, Nikolay Conev, J. Armstrong, Natalie Byrne, Norah J. Shire, Haiyi Jiang, Jonathan W. Goldman, Emilio Batagelj, Ignacio Casarini, Anea Viviana Pastor, S. Sena, Juan José Zarbá, Otto C. Burghuber, Sylvia Hartl, Maximilian J. Hochmair, Bernd Lamprecht, Michael Studnicka, Luís Alberto Schlittler, Fabrício Augusto Martinelli de Oliveira, Aknar Calabrich, Gustavo Girotto, Peo Dos Reis, Carlos Fausto Nino Gorini, Peo Rafael Martins De Marchi, Clarissa Baldotto, Cláudia Vaz de Melo Sette, Mauro Zukin, Nikolay Conev, Assen Dudov, Rumyana Ilieva, Krassimir Koynov, Rositsa Krasteva, Ivan Tonev, Spartak Valev, Violetka Venkova, Minghong Bi, Chengshui Chen, Yuan Chen, Zhendong Chen, Jian Fang, Jifeng Feng, Zhigang Han, Jie Hu, Yi Hu, Xing Li, Zongan Liang, Lin Zhong, Rui Ma, Shenglin Ma, Kejun Nan, Yongqian Shu, Kai Wang, Mengzhao Wang, Gang Wu, Nong Yang, Zhixiong Yang, Helong Zhang, Wei Zhang, Jun Zhao, Yanqiu Zhao, Caicun Zhou, Jianying Zhou, Xiangdong Zhou, Libor Havel, Vı́tězslav Kolek, Leona Koubková, Jaromı́r Roubec, Jana Skřičková, Milada Zemanová, C. Chouaïd, Werner Hilgers, H. Léna, Denis Moro‐Sibilot, G. Robinet, Pierre-Jean Souquet, Jürgen Alt, Helge Bischoff, Christian Grohé, Eckart Laack, Susanne Lang, Jens Panse, Niels Reinmuth, Christian Schulz
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Marina Chiara Garassino, Олександр Войтко, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Każarnowicz, György Losonczy, Nikolay Conev, J. Armstrong, Natalie Byrne, Piruntha Thiyagarajah, Haiyi Jiang, Luis Paz‐Ares, Mikhail Dvorkin, Dmytro Trukhin, Galina Statsenko, Nataliia Voitko, Artem Poltoratskiy, Igor Bondarenko, Yuanbin Chen, Andrzej Każarnowicz, Luis Paz‐Ares, Mustafa Özgüroğlu, Nikolay Conev, Maximilian J. Hochmair, Otto C. Burghuber, Libor Havel, İrfan Çiçin, György Losonczy, В. Моисеенко, Mustafa Erman, Dariusz M. Kowalski, Marek Z. Wojtukiewicz, Hryhoriy Adamchuk, Alexander Vasilyev, Serhii Shevnia, Spartak Valev, Niels Reinmuth, Jun Ho Ji, Maria Amelia Insa Molla, Grygorii Ursol, Anne C. Chiang, Sylvia Hartl, Zsolt Horváth, Gábor Pajkos, Francesco Verderame, Katsuyuki Hotta, Sang‐We Kim, Alexey Smolin, Tuncay Göksel, Shaker R. Dakhil, Jaromı́r Roubec, Krisztina Bogos, Marina Chiara Garassino, Robin Cornelissen, Jong-Seok Lee, M.R. García Campelo, Marta López Brea, Ahmet Alacacıoğlu, Ignacio Casarini, Rumyana Ilieva, Ivan Tonev, A Somfay, Jair Bar, Alona Zer Kuch, Mauro Minelli, Roberta Bartolucci, Fausto Roila, Haruhiro Saito, Koichi Azuma, Gyeong‐Won Lee, Alexander Luft, Michal Urda, Juan Ignacio Delgado Mingorance, M. Majem Tarruella, David R. Spigel, Krassimir Koynov, Milada Zemanová, Jens Panse, Christian Schulz, Zsolt Pápai Székely, Veronika Sárosi, Angelo Delmonte, Anna Bettini, Makoto Nishio, Isamu Okamoto, Lizza Hendriks, Sławomir Mańdziuk
Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer
Primo N. Lara, Jean‐Yves Douillard, Kazuhiko Nakagawa, Joachim von Pawel, Mark J. McKeage, István Albert, György Losonczy, Martin Reck, Dae Seog Heo, Xiaolin Fan, Abderrahim Fandi, Giorgio V. Scagliotti
Sexual dimorphism in renal ischemia-reperfusion injury in rats: Possible role of endothelin
Veronika Müller, György Losonczy, Uwe Heemann, Ádám Vannay, Andrea Fekete, György Reusz, Tivadar Tulassay, Attila J. Szabó